Trump Is Promising to Lower Drug Prices. Don’t Count on It

Trump leadership This week considered Americans to significantly reduce high prices for the recipe medications. Undoubtedly, it is a promise to reach a short time.

Tuesday, President Donald Trump signed An executive order, which has taken steps through the Federal Government’s Health and Human Services Department, plans to reduce drug prices. Although some suggestions are voiced, others are impossible for others to move the needle. Trump and GOP deputies also force other measures that can gather medication for many Americans or other events.

The main board of the executive decision includes improvement Medicare Drugs Assessment Talk Program: Government Medicare is an assistant program that allows you to directly discuss the prices for the best recipe medications on the market. The first round of talks occurred last year and resulted in a discount on ten drugs, even if price discounts do not enter into force until 2026, this year will result in discounts in 2028.

One of the most important drugs in this second round is the semaglutide, 2 types of diabetes and diabetes are a diabetody and Diabeline medication with Rybelsus. Semaglutide-based medications cost over $ 1000 per month, and many suitable patients cannot access them due to high list prices and coverage. Thus, if drug prices are truly cut, it will represent an original success. Again, any discount will not come with the presidency (hopefully) until 2028. Meanwhile, his HHS actually made it difficult to pay these drugs for people in Medicare.

Currently, Medicare can not directly cover any weight loss medicinal medications, although it can take similar medications for certain obesity-related conditions such as ozemp or ozemp and similar medications or heart disease. Biden’s leadership proposed Last year, as a rule, which is 7 million Americans, which are 7 million Americans, which are 7 million Americans, which are 7 million Americans in Medicare and Medicaid in Medicare and Medicaid in 2026, this month, but Trump management humiliated This offer. HHS Head Robert F. Kennedy declared Last week’s management, RFK Jr. He thinks he reviewed a kind of “frame” to expand the scope are questioned repeatedly the value of these drugs in the past.

Another wrinkle is called “Pill Pulse” in the plans of the TRUP’s low drug prices. Medications are not suitable for the negotiation program after being in the market for a certain period of time. For small molecule recipe medications, it is usually accepted as a pill, this delay is currently seven years (actually the price is nine years before the price is cut nine years ago). The delay, which is more complex, expensive, producing medicines for biologists, usually adopted by injections for 11 years (13 years). At the executive order, Trump promised to “match the treatment of these two types of drugs.”

But as David Daye In the future and others, the executive order, in fact, shortens the delay in the HHS program in accordance with the program. And the current Pharca supported gop bills that try to solve this inconsistency stretching Biologists of small molecule drugs (resolved solutions have tried to reduce both).

According to a KFF analysis released on Wednesday a the four-year delay Including the semaglutide, the medications of the Negotiation Program could have taken more than half. Forward, a longer exclusivity period for these drugs will cost the government to many potential deposits, and as a result, many American wallets that rely on them will damage them.

Senator Ron Wyden (D-Oregon), a member of the Senate Financial Committee on Wednesday, agreement This Trump’s executive order is only defined to weaken medicinal prices.

“As the first term, Trump, when it comes to reducing the value of recipe medications, Trump is all bark and no bites,” Wyden said. “This executive order, first of all, first of all, weakens higher prices for medicinal companies, which weakens higher prices for drug companies.”

As the value of the execution, a number of nuggets are trying to create insulin’s value, as reducing insulin value (initiative starting during the first tap) or accelerates the approval of general drugs. However, even these proposals are also hit by the actions of the White House.

The FDA poured about 20% of the workforce, for example, as part of a “reconstruction” established with a Doe already hinder the ability to to process potential medicinal approvals. And there is guidance The land began to put work The drugs imported to the United States can cause tariffs, especially higher expenses and drug failures abroad.

Nothing about Trump’s past or last track record shows that recipe medications in America will be significantly reduced. If we really fail, some medications can soon be more expensive.